What Is New with Anti-VEGF Therapy for DME

A wealth of evidence supports anti-VEGF therapy in DME.

Read Article
  • New Paradigms in the Management and Treatment of Diabetic Macular Edema

    Read Article


Intravitreal immunoregulatory therapy may offer new treatment options for noninfectious uveitis: http://t.co/HR4dn5a2qA

Articles From This Issue


Internal Limiting Membrane: Making the Decision to Peel

The internal limiting membrane (ILM) is a very thin and transparent acellular membrane on the surface of the retina. It plays an important role in the early stages of retina…

Laser Pointer Retinal Injures


In the past few years, injuries or incidents involving accidental or intentional laser pointer exposure have been on the rise, and these events are now becoming dangerously …


Uveitis Resource Center




New Approaches to Vision with Microchips Holds out Prospects for the Blind

To date, chip-based retinal implants have only permitted a rudimentary restoration of vision, but a …

Eylea Sales Exceed Expectations; Regeneron Boosts 2015 Guidance for the Drug

Sales of Eylea (aflibercept) in the United States increased 51% to $541 million in the first quarter…

Video Series

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Bryan Bechtel

Alan B. Guralnick

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.

Website Design by Sides Media